Araki Yoshio, Tsujikawa Tomoyuki, Sugihara Hiroyuki, Fujiyama Yoshihide, Hattori Takanori
Department of Pathology, Shiga University of Medical Science, Seta Tsukinowa, Otsu, Shiga, Japan;
Int J Biomed Sci. 2008 Sep;4(3):245-7.
We report two recent, successful cases in treating active chronic hepatitis C patients (genotype 2a) with a lower-dose and long-term intermittent interferon therapy. Case 1: A 67-year-old female received IFN-alpha 3 MU twice a week. Biochemical and virological remissions were achieved after 4 weeks and 14 months, respectively. We changed the IFN to pegylated-interferon alpha-2a (P-IFN) 45 μg once a week. After which, we successfully reduced the frequency of injections to once a month while maintaining both remissions. Case 2: A 61-year-old male had received a conventional genetical recombination interferon therapy. However, the hepatitis recurred. He was given IFN-alpha 3 MU once a week. A biochemical remission was achieved after 3 months. After 7 months, we changed the IFN to P-IFN 90 μg once a week, and a virological remission soon occurred. Then, we also could reduce the frequency to once every two months. Our novel strategy using P-IFN is safe and economic.
我们报告了两例近期采用低剂量长期间歇干扰素疗法成功治疗活动性慢性丙型肝炎患者（2a基因型）的病例。病例1：一名67岁女性患者，每周接受两次300万单位的α干扰素治疗。分别在4周和14个月后实现了生化缓解和病毒学缓解。之后，我们将干扰素换成聚乙二醇化α-2a干扰素（P-IFN），每周一次，剂量为45微克。此后，我们成功地将注射频率降至每月一次，同时维持了两种缓解状态。病例2：一名61岁男性患者接受过传统的基因重组干扰素治疗。然而，肝炎复发。他接受每周一次300万单位的α干扰素治疗。3个月后实现了生化缓解。7个月后，我们将干扰素换成每周一次90微克的P-IFN，很快出现了病毒学缓解。然后，我们也能够将频率降至每两个月一次。我们使用P-IFN的新策略安全且经济。
